Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
Riamet® or Malarone® are both recommended as the first line treatment for uncomplicated
malaria in France, according to the French consensus Conference revised in 2007 on the
treatment of imported malaria.
The aim of the study is to compare both tolerance and efficacy of Malarone® and Riamet® in
the treatment of uncomplicated imported malaria and to determine clinical and parasitological
predictive factors associated with a less effectiveness. It's a multicentric, randomised
study in adults with uncomplicated malaria. Treatment will be administered for 3 days, and
patients will be followed for 28 days, to evaluate the therapeutic evolution. 640 patients
will be included among 15 centres.
Phase:
Phase 4
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Treatments:
Artemether Artemisinins Atovaquone Atovaquone, proguanil drug combination Proguanil